Adaptogen

Panax quinquefolius

Panax quinquefolius

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

200-400

watchEffect Window

2-8 weeks

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

American ginseng (Panax quinquefolius) has moderate evidence for glycemic support and variable evidence for fatigue and cognition outcomes.

Human evidence is often limited to small, heterogeneous trials. Reported benefits commonly include modest changes in dyspepsia symptoms, glycemic markers, lipids, or perceived stress. Minority findings include antimicrobial activity, immune modulation, and effects on liver enzymes, but these are frequently preclinical. Outcomes depend on standardization, dose, and baseline health.

Ginsenoside-containing adaptogenic root with context-dependent fatigue and stress-support evidence. Direct high-confidence nootropic effect is unproven.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Possible fatigue reduction in select adults
  • Modest attention/focus support in short fatigue contexts

Secondary Outcomes

  • Potential anxiety/subjective energy modulation
  • Limited nootropic effect confidence

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy/lactation
  • Uncontrolled anxiety
  • Anticoagulant/hormonal therapy

Side effects

  • Insomnia
  • Headache
  • Palpitations

Interactions

  • Anticoagulants
  • Hypoglycemics
  • Hormonal therapies

Avoid if

  • Pregnancy
  • Sleep-sensitive users
  • Uncontrolled hypertension

Evidence

Study-level References

american-ginseng-panax-quinquefolius-SRC-001Randomized controlled and meta-analytic assessments.

Controlled studies and systematic synthesis of Panax quinquefolius for fatigue and cognitive endpoints.

Population: Healthy and mildly fatigued adults.

Dose protocol: Standardized extracts (200-400 mg/day).

Key findings: Modest improvements in symptom and task-related outcomes in subsets.

Notes: Variation in extract markers and outcome definitions.

Paper content

Modest improvements in symptom and task-related outcomes in subsets.

american-ginseng-panax-quinquefolius-SRC-002Synthesis and systematic reviews.

Reviews of stimulant-like herbal adaptogens comparing evidence confidence and publication quality.

Population: Diverse herbal trials.

Dose protocol: Different ginseng preparations and comparator designs.

Key findings: Some positive effects with significant inconsistency across trials.

Notes: Heterogeneity and selective reporting risk.

Paper content

Some positive effects with significant inconsistency across trials.

american-ginseng-panax-quinquefolius-SRC-003Double-blind, randomized, placebo-controlled, cross-over trial.
Sourceopen_in_new

Vuksan V, Xu ZZ, Jovanovski E, et al. Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial. Eur J Nutr. 2019;58(3):1237-1245. doi:10.1007/s00394-018-1642-0. PMID:29478187.

Population: Adults with type 2 diabetes maintained on conventional diabetes treatment.

Dose protocol: 3 g/day American ginseng extract (1 g per meal) for 8 weeks in a cross-over design.

Key findings: Significant reductions in HbA1c (-0.29%), fasting glucose (-0.71 mmol/L), and systolic BP (-5.6 mmHg) versus placebo in T2D patients.

Notes: Small sample (N=24) but rigorous cross-over design with registered protocol. Industry affiliation noted.

Paper content

This double-blind, cross-over RCT tested 3 g/day American ginseng extract for 8 weeks in 24 adults with type 2 diabetes. Ginseng significantly reduced HbA1c by 0.29%, fasting glucose by 0.71 mmol/L, and systolic blood pressure by 5.6 mmHg compared to placebo. The extract also increased serum nitric oxide metabolites. Liver and kidney safety profiles were unaffected, supporting use as an adjunct to conventional diabetes management.

american-ginseng-panax-quinquefolius-SRC-004Double-blind, randomized, placebo-controlled parallel trial with in vitro component.
Sourceopen_in_new

Bell L, Whyte A, Duysburgh C, et al. A randomized, placebo-controlled trial investigating the acute and chronic benefits of American Ginseng (Cereboost) on mood and cognition in healthy young adults. Eur J Nutr. 2022;61(1):413-428. doi:10.1007/s00394-021-02654-5. PMID:34396468.

Population: Healthy young adults.

Dose protocol: Cereboost standardized American ginseng extract for 14 days.

Key findings: Improved working memory and attention acutely and after chronic supplementation. Acetylcholine-sensitive tasks improved chronically.

Notes: Industry-funded (Naturex SA). Parallel in vitro gut microbiota investigation adds mechanistic insight.

Paper content

This double-blind, placebo-controlled RCT in 61 healthy young adults tested Cereboost (American ginseng extract) acutely and after 14 days of daily supplementation. Ginseng improved working memory and attention within hours of dosing, and these effects were amplified after two weeks of chronic use. Chronic supplementation also improved acetylcholine-sensitive attention tasks and aspects of mood. An in vitro gut microbiota investigation showed increased short-chain fatty acid production, suggesting a possible gut-brain mechanism.

Guides

Setup

Help